DARE - Daré Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0100
-0.0600 (-5.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.0700
Open1.0700
Bid1.0100 x 1200
Ask1.0700 x 3200
Day's Range1.0100 - 1.1161
52 Week Range0.6000 - 3.2500
Volume399,906
Avg. Volume1,129,767
Market Cap16.85M
Beta (3Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-1.5600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of DARE earnings conference call or presentation 4-Apr-19 12:30pm GMT

    Q4 2018 Dare Bioscience Inc Earnings Call

  • GlobeNewswire4 days ago

    Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring designed to provide multiple weeks of contraceptive protection. The presentation entitled, “Contraception 2019: What about LARC, Rings, Gel, even Apps?”, was given by noted physician and women’s health expert Dr. James A. Simon during the Survival Skills for Today’s Gynecologist continuing medical education conference in New York City on Sunday, April 14th.

  • Zacks Small Cap Research10 days ago

    DARE: Pipeline Timelines Intact. Several Development-Related Milestones Upcoming

    By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q4 / Pipeline Update Daré Bioscience (NASDAQ:DARE) reported financial results for their fourth quarter and provided an operational update. ...

  • GlobeNewswire10 days ago

    Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock

    Daré Bioscience, Inc. (DARE), today announced the pricing of an underwritten public offering of 4,575,000 shares of its common stock at a price of $1.10 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $4.4 million, assuming no exercise of the overallotment option, and approximately $5.1 million assuming the overallotment option is exercised in full. Roth Capital Partners is acting as the sole book-runner for the offering.

  • GlobeNewswire10 days ago

    Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it intends to offer shares of its common stock in an underwritten public offering.  Daré expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions.

  • GlobeNewswire11 days ago

    Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel 17β-estradiol and progesterone intravaginal ring in sheep” was published online in the Journal of Pharmaceutical Sciences (JPharmSci®). The goal of the research described in the article was to characterize the release, pharmacokinetics and local tolerability of DARE-HRT1, a potential and novel hormone replacement therapy.  DARE-HRT1, an ethylene-vinyl acetate (EVA) intravaginal ring (IVR) drug delivery technology delivering 17β-estradiol (E2) and progesterone (P), was evaluated in drug-naïve ovariectomized female Dorset crossbred sheep. DARE-HRT1 is being developed as a combination bio-identical estradiol and bio-identical progesterone IVR for hormone replacement therapy (HRT) to treat vasomotor symptoms (VMS), commonly called hot-flashes and associated with menopause, as part of an HRT regimen.

  • GlobeNewswire17 days ago

    Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq

    SAN DIEGO, April 01, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it received notice from The Nasdaq Stock Market.

  • GlobeNewswire18 days ago

    Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast

    SAN DIEGO, April 01, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • GlobeNewswire21 days ago

    World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced that Dr. Robert Langer, co-inventor of Daré‘s novel, segmented intravaginal ring (IVR) drug delivery technology and one of the 10 Institute Professors at the Massachusetts Institute of Technology (MIT) joined the company’s Scientific Advisory Board.

  • ACCESSWIRElast month

    Four Healthcare Stocks Heating Up On Monday

    Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.

  • MarketWatchlast month

    Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study

    Shares of Daré Bioscience Inc. rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday, after the biopharmaceutical company announced positive findings for the use of its DARE-VVA1 product candidate in treating vulvar and vaginal atrophy (VVA). The stock was the biggest percentage gainer listed on major U.S. exchanges, even though it pared earlier gains of as much as 253%. Volume swelled to 37.8 million shares, compared with the full-day average of about 82,500 shares and enough to make the stock the most active on the Nasdaq exchange. The company said a self-administered vaginal suppository containing tamoxifen administered to four healthy postmenopausal women with VVA showed "significant improvements" in reducing vaginal pH and vaginal dryness, without significant absorption of tamoxifen. "If successful, DARE-VVA1 could be the first and only vaginally administered tamoxifen product approved by the FDA for the treatment of VVA in hormone-receptor positive breast cancer patients," the company said in a statement. The stock has now more than tripled year to date (up 218%), while the iShares Nasdaq Biotechnology ETF has climbed 18% and the S&P 500 has gained 13%.

  • GlobeNewswirelast month

    Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference

    SAN DIEGO, March 18, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswirelast month

    Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the publication of clinical findings for vaginally-administered tamoxifen in Clinical and Experimental Obstetrics and Gynecology, a leading international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology. Daré’s product candidate, DARE-VVA1, incorporates tamoxifen in a proprietary formulation designed for vaginal delivery. Daré holds the exclusive worldwide rights to patents issued in the U.S. and Japan covering the use and delivery of DARE-VVA1 for vulvar and vaginal atrophy (VVA) and a U.S. patent covering composition, use and delivery of DARE-VVA1 for VVA.

  • GlobeNewswirelast month

    Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851, part of a grant providing up to $1.9 million in the aggregate for Ovaprene® research from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). This second award, an additional $982,851, followed the NIH’s review of an interim data analysis and other results of the first phase of work. The award will be applied to important clinical development efforts supporting Ovaprene, a potential first-in-class hormone-free contraceptive solution.

  • GlobeNewswirelast month

    Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference

    SAN DIEGO, March 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 16th Annual BIO Asia International Conference on Tuesday, March 5, 2019 at 4:15 p.m. Japanese Standard Time in Tokyo, Japan. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.  “Given our focus on identifying development and global commercialization partners for our portfolio of women’s health product candidates, we are pleased to have the opportunity to present and participate in the partnering meetings organized by the conference,” said Sabrina Johnson.

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference

    SAN DIEGO, Feb. 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire4 months ago

    Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré.

  • What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)?
    Simply Wall St.4 months ago

    What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)?

    The big shareholder groups in Daré Bioscience, Inc. (NASDAQ:DARE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of DARE earnings conference call or presentation 13-Nov-18 1:30pm GMT

    Q3 2018 Dare Bioscience Inc Earnings Call

  • Zacks Small Cap Research4 months ago

    DARE: DARE Adds Late-Stage Bacterial Vaginosis Candidate To Ever-Expanding Women’s Health Pipeline

    Dare Bioscience (DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline and their potential eventual related commercialization opportunities. Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC. DARE is also required to pay potential future milestones based on “clinical, regulatory, commercial launch and sales events”, and is also subject to paying royalties on any eventual sales. Bacterial Vaginosis, What It Is, How Prevalent and How Is it Treated?

  • ACCESSWIRE4 months ago

    New Healthcare Trends Pushing Stocks Higher On Thursday

    CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.

  • Zacks Small Cap Research5 months ago

    DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway

    By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...

  • GlobeNewswire5 months ago

    Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the initiation of a content validity study intended to support the use of specific patient reported outcome (PRO) measures to assess efficacy in female sexual arousal disorder (FSAD) patients in the Phase 2b and Phase 3 program for Sildenafil Cream, 3.6%.